ReviewBMC medical ethics2016
Has the biobank bubble burst? Withstanding the challenges for sustainable biobanking in the digital era.
Review in BMC medical ethics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Opportunities for a national genomic data governance framework in Australia: a systematic review.BMC medical ethics · 2025Pooled it
- A systematic literature review of the 'commercialisation effect' on public attitudes towards biobank and genomic data repositories.Public understanding of science (Bristol, England) · 2024Pooled it
- Population genetic considerations for using biobanks as international resources in the pandemic era and beyond.BMC genomics · 2021Pooled it
- From Scale to Situated: Sociotechnical Imaginaries and the Configuration of Algorithmic Health Research.Sociology of health & illness · 2026Article
- Navigating tensions between scientific advancement and ethical practice in biobanking: a qualitative study in Japan.Frontiers in genetics · 2026Article
- Towards a trusted genomics repository: Identifying commercialisation fears and preferred forms of governance across segments of the community.Public understanding of science (Bristol, England) · 2025Article
- Pass the tissue: restoring researcher access to legal human donations.Journal of medical ethics · 2025Article
- Japanese attitudes toward cell donation in human brain organoid research: many oppose broad consent.Frontiers in genetics · 2025Article
- Roadmap for low-carbon ultra-low temperature storage in biobanking.Journal of translational medicine · 2024Review
- Trust and Support for Cancer Research Biobanks: Insights from Cancer Patients in Poland.Medical science monitor : international medical journal of experimental and clinical research · 2024Article
- Article
- Commercialisation fears and preferred forms of governance: a mixed methods investigation to identify a trusted Australian genomics repository.Frontiers in public health · 2024Article
- Risk mapping for better governance in biobanking: the case of biobank.cy.Frontiers in genetics · 2024Article
- Commoning genomic solidarity to improve global health equality.Cell genomics · 2023Review
- Old and new challenges regarding comparable and viable data sharing in population-scale genomic research.European journal of human genetics : EJHG · 2023Article
- UPO Biobank: The Challenge of Integrating Biobanking into the Academic Environment to Support Translational Research.Journal of personalized medicine · 2023Article
- Priorities in Biobanking Research: A Report on the 2021 ISBER Round Table.Biopreservation and biobanking · 2023Article
- The limitations of large-scale volunteer databases to address inequalities and global challenges in health and aging.Nature aging · 2022Review
- Better governance starts with better words: why responsible human tissue research demands a change of language.BMC medical ethics · 2022Article
- Biobank and Pathology Facility: A Successful Combination.Journal of biomolecular techniques : JBT · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Biobanks have been heralded as essential tools for translating biomedical research into practice, driving precision medicine to improve pathways for global healthcare treatment and services. Many nations have established specific governance systems to facilitate research and to address the complex ethical, legal and social challenges that they present, but this has not lead to uniformity across the world. Despite significant progress in responding to the ethical, legal and social implications of biobanking, operational, sustainability and funding challenges continue to emerge. No coherent strategy has yet been identified for addressing them. This has brought into question the overall viability and usefulness of biobanks in light of the significant resources required to keep them running. This review sets out the challenges that the biobanking community has had to overcome since their inception in the early 2000s. The first section provides a brief outline of the diversity in biobank and regulatory architecture in seven countries: Australia, Germany, Japan, Singapore, Taiwan, the UK, and the USA. The article then discusses four waves of responses to biobanking challenges. This article had its genesis in a discussion on biobanks during the Centre for Health, Law and Emerging Technologies (HeLEX) conference in Oxford UK, co-sponsored by the Centre for Law and Genetics (University of Tasmania). This article aims to provide a review of the issues associated with biobank practices and governance, with a view to informing the future course of both large-scale and smaller scale biobanks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.